Phase I trial of fenretinide Lym-X-Sorb oral powder in adults with solid tumors and lymphomas

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 961-966

  Kummar, Shivaani ^a   Gutierrez, Martin E ^a   Maurer, Barry J ^b   Reynolds, C Patrick ^b   Kang, Min ^b   Singh, Hardeep ^b   Crandon, Sonja ^a   Murgo, Anthony J ^a   Doroshow, James H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Clinical trial; Fenretinide; LXS oral powder; Phase I

Indexed keywords

ANTIHISTAMINIC AGENT; FENRETINIDE; LOPERAMIDE; LYM X SORB; STEROID; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADRENAL CORTEX CARCINOMA; ADULT; ALLERGIC REACTION; ANOREXIA; ARTICLE; BLOOD SAMPLING; BREAST ADENOCARCINOMA; CANCER RECURRENCE; CHONDROSARCOMA; CLINICAL ARTICLE; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EOSINOPHILIA; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOPHOSPHATEMIA; LEG ULCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NIGHT BLINDNESS; OPEN STUDY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PATIENT COMPLIANCE; PERITONEUM MESOTHELIOMA; PHASE 1 CLINICAL TRIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; SKIN BIOPSY; SKIN INFECTION; SKIN INFILTRATE; SOLID TUMOR; THROMBOCYTOPENIA; THYMOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENRETINIDE; HUMANS; LIPIDS; LYMPHOMA; MALE; MIDDLE AGED; POWDERS;

EID: 79956073395     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maurer BJ, Melton L, Billups C, Cabot MC and Reynolds CP: Synergistic cytotoxicity in solid tumor cell lines between N-(4-Hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92: 1897-1909, 2000.
2. Dawson MI and Fontana JA: The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: their structure-activity relationships and retinoid receptor-independent anticancer activities. Mini-Reviews in Medicinal Chemistry 10: 455-491, 2010.
3. Di Vinci A, Geido E, Infusini E and Giaretti W: Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int J Cancer 59: 422-426, 1994. (Pubitemid 24331837)
4. McCormick DL, Johnson WD, Rao KVN, Bowman-Gram T, Steele VE, Lubet RA and Kelloff GJ: Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and α-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis 17: 2513-2517, 1996. (Pubitemid 26402255)
5. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U and Pierotti MA: N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036-6041, 1993.
6. Torrisi R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F and Decensi A: Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3: 507-510, 1994. (Pubitemid 24280975)
7. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH and Reynolds CP: Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430, 2006. (Pubitemid 46638899)
8. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF and Formelli F: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039, 2003. (Pubitemid 36687622)
9. Jasti B, LoRusso P, Parchment R and Wozniak A: Phase I clinical trial of fenretinide (NSC 374551) in advanced solid tumors. Proc Am Soc Clin Oncol 20: abstr 485, 2001.
10. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun B-C, McKee RT, Burgess SW, Shaw WA and Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 13: 3079-3086, 2007.
11. Lepage G, Yesair DW, Ronco N, Champagne J, Bureau N, Chemtob S, Bérubé D and Roy CC: Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr 141: 178-185, 2002.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
13. Vratilova J, Frgala T, Maurer BJ and Reynolds CP: Liquid chromatography method for quantifying N-(4-hydroxyphenyl) retinamide and N-(4-methoxyphenyl) retinamide in tissues. J Chromatogr B 808: 125-130, 2004. (Pubitemid 38952906)
14. Marachelian A, Kang M, Hwang K, Villabianca J, Groshen S, Matthay K, Maris J, DeSantes K, Reynolds C and Maurer B: Phase I study of fenretinide (4-HPR)/Lym-X-Sorb™ (LXS) oral powder in patients with recurrent or resistant neuroblastoma. New Approaches to Neuroblastoma Therapy (NANT) consortium trial. J Clin Oncol 27: 15s (abstr. 10009), 2009.
15. Sani BP, Shealy YF and Hill DL: N-(4-hydroxyphenyl) retinamide: interactions with retinoid-binding proteins/receptors. Carcinogenesis 16: 2531-2534, 1995.
16. Ritter SJ and Smith JE: Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats. Biochim Biophys Acta 1290: 157-164, 1996.
17. Holven KB, Natarajan V, Gundersen TE, Moskaug JØ, Norum KR and Blomhoff R: Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: Evidence for reduced affinity of the complex for transthyretin. Int J Cancer 71: 654-659, 1997. (Pubitemid 27239378)
18. Schaffer EM, Ritter SJ and Smith JE: N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats. J Nutr 123: 1497-1503, 1993. (Pubitemid 23268001)